Becton, Dickinson and Company (BD) is one of the few medtech companies in 2021 that has been busy with mergers and acquisitions. BD said it is keeping an eye on the chronic venous insufficiency (CVI) treatment market with its latest addition. The Franklin Lakes, NJ-based company said it acquired Venclose for an undisclosed amount in a deal not expected to affect its 2022 financial results.
San Jose, CA-based Venclose has an RF ablation technology platform that treats CVI – a disease that results from malfunctioning valves and can lead to varicose veins. The Venclose system is compactly designed and provides two heating lengths (2.5 cm and 10 cm) in one 6 FR size catheter.
The device allows physicians to efficiently ablate more veins during each heating cycle and reduce the total number of ablations required for treatment in the vein. The dual heating length means clinicians can ablate both long and short vein segments with the same catheter, reducing inventory management burden compared to catheters with shorter and/or static heating lengths.
“We are committed to setting a new standard of excellence for people with venous disease, and that starts with bringing innovative technologies to physicians,” said Paddy O’Brien, global president of Peripheral Intervention for BD. “Our acquisition of Venclose enables us to offer a more robust portfolio of solutions to physicians treating the full range of venous conditions. The Venclose RF ablation system strategically complements our industry-leading portfolio of venous disease technologies and aligns with our focus on innovations that provide transformative solutions to improve outcomes for chronic disease and enable the transition to new healthcare environments.”
BD has acquired six other companies this year. Prior to the Venclose announcement, the company said it was acquiring Tepha.
The Lexington, MA-based company developed GalaFlex, a bioresorbable scaffold for soft tissue support and for repairing, augmenting and strengthening deficiencies where weakness or voids exist that require the addition of material to achieve the desired surgical outcome. The acquisition would help drive innovation and growth for BD’s surgical mesh portfolio.
In addition, BD said it will divest its diabetes care business to a publicly traded company in the first half of 2022. The unit has a rich history dating back to 1924, when BD introduced the world’s first specialty syringe.
Boston Scientific and Hologic have also been quite active with M&A. Both are involved in about five deals each. Hologic’s latest merger and acquisition target in Waltham, MA was Bolder Surgical for approximately $160 million.
Finally, Marlborough, MA-based Boston Scientific said it had signed an agreement to acquire its 5th company – Baylis Medical – this year for $1.75 billion.